Thompson Davis & Co’s Genetic Technologies Ltd. GENE Stock Holding History

Thompson Davis & Co’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-690	Closed	-$27K	–	1281
2014 Q4	$27K	Buy	+690	New	+$27.6K	0.03%	438

Other funds holding GENE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Thompson Davis & Co's GENE Position: Q1 2015 in Review

Thompson Davis & Co sold out of Genetic Technologies Ltd. (GENE) in Q1 2015, closing a stake of 690 shares — an estimated $27K sold.

Thompson Davis & Co first reported a position in GENE in Q4 2014 and held it in 1 quarter. The position peaked at $27K in Q4 2014. 13 funds tracked by Wall St. Rank hold GENE as of Q1 2015.

Thompson Davis & Co reported no remaining Genetic Technologies Ltd. position as of Q1 2015 after selling out during the quarter.
Thompson Davis & Co sold 690 Genetic Technologies Ltd. shares in Q1 2015, an estimated $27K.
Thompson Davis & Co first reported a position in Genetic Technologies Ltd. in Q4 2014 and held it in 1 quarter.
Thompson Davis & Co's Genetic Technologies Ltd. position peaked at $27K in Q4 2014.
13 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q1 2015.

Based on Thompson Davis & Co's 13F filing for Q1 2015, filed 28 Apr 2015.